Novavax vaccine arrives by the end of September: it would be very effective

Contains nanoparticles obtained from a lab-produced version of the Spike protein

In support of countries for now neglected by the distribution of vaccines, Novavax's NVX-CoV2373 should arrive in September and will require authorizations all over the world.

Sputnik news – 14 giugno 2021

Very early a new vaccine against the coronavirus will be added to the list of those approved internationally, and it is the American Novavax which for the moment has made it known that the experimental results have also given positive results on the variants with the 90% coverage.

In September it could apply for approval for emergency use from the US drug regulator, the FDA, the European EMA and other countries.

The study was conducted on 29,960 people and the vaccine demonstrated an efficacy of 90.4%.

Novavax will initially be able to make it available to the international community 100 million doses of vaccine.

Novavax's third way: protein-based vaccine

Novavax brings a novelty in terms of pharmaceutical techniques and technologies used in the fight against the coronavirus. The pharmaceutical company has in fact opted for a protein-based vaccine, which contains tiny particles obtained from a laboratory-produced version of the Spike protein present on the surface of the pandemic coronavirus.

The vaccine also uses an adjuvant (Matrix-M1), which is a substance that helps strengthen the immune responses stimulated by the vaccine.

No blood clotting or heart disease problems were detected in the subjects who received the double injection.

Where will the NVX-CoV2373 vaccine go

to use the Novavax NVX-CoV2373 vaccine, easy to transport and store, will be mainly low- and middle-income countries, said the pharmaceutical company's president of research and development Gregory M. Glenn.

The French vaccine

The European Commission is also in talks with the French company Valneva with which, however, no contract has yet been signed for any 30 million doses.

Valneva's vaccine, Vla2001, is based on a fourth technology that uses inactivated coronavirus Sars-CoV-2 particles.

Related news
Title Topics Year Links Document Notes
Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the US and Mexico COVID-19 2020 Updated May 10, 2021
Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the UK COVID-19 2020 Updated April 5, 2021
Current Protocol for Phase 2b Clinical Trial of NVX-CoV2373 in South Africa COVID-19 2020 Updated January 25, 2021

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Note:

NVX-CoV 7 è un vaccino progettato per fornire protezione contro il COVID- 19. Progettato dalla sequenza genetica di COVID-19, si è utilizzato la tecnologia di nanoparticelle ricombinanti per generare antigeni derivati dalla proteina spike del coronavirus. In combinazione con l’adiuvante brevettato Matrix-M™, NVX-CoV 7 ha dimostrato in studi preclinici che si lega in modo efficiente con i recettori umani presi di mira dal virus, un aspetto critico per un efficace protezione del vaccino.

L’adiuvante Matrix-M™ brevettato, a base di saponina di Novavax, ha dimostrato un effetto potente e ben tollerato stimolando l’ingresso delle cellule che presentano l’antigene nel sito di iniezione e migliorando la presentazione dell antigene nei linfonodi locali, aumentando la risposta immunitaria. In particolare Matrix-M è composto da 40 particelle nanometriche a base di saponina estratta dalla corteccia di Quillaja saponaria Molina insieme a colesterolo e fosfolipidi.

Novavax è un’azienda statunitense che opera nel campo delle biotecnologie. Fondata nel 1987, ha sede a Gaithersburg nel Maryland: è stata inserita nell’Indice Russell 2000 ed è quotata al Nasdaq.

L’azienda si occupa principalmente di sviluppare vaccini e possiede strutture a Rockville, nel Maryland, e a Uppsala, in Svezia. La sua ricerca non ha mai prodotto alcun vaccino che sia giunto in commercio. A partire dal 2020, ha iniziato lo studio e lo sviluppo di un vaccino contro il SARS-CoV-2, virus responsabile della pandemia di COVID-19. Tale vaccino chiamato NVX-CoV2373, nel gennaio 2021 è arrivato alla Fase III di sviluppo.

 

 

Exit mobile version